GPC Biotech Licenses IP from Ariad

NEW YORK, Feb. 4 - GPC Biotech of Martinsried, Germanyhas non-exclusively licensed patents from Ariad pharmaceuticals in the area of cell-signaling regulation technology, the company said today.

This additional IP allows the company to add this technology to its LeadCode drug discovery platform, a modified yeast two-hybrid proteomics methodology that screens for interactions between a small molecule and the full complement of human proteins.

This new IP licensing agreement follows on the heels of GPC's collaboration with Eli Lilly Jan. 31 to use LeadCode for mechanism of action studies on a class of metabolic disease lead compounds.